HIV Drugs Market

Report Overview

The global HIV drugs market was pegged at US$ 30.89 billion in 2021 and is expected to register a revenue CAGR of 6.2% during the forecast period.

Market Fundamentals 

One of the fatal chronic viral diseases and an incurable virus is HIV, also known as the Human Immunodeficiency Virus infection. It attacks the immune system of an individual and makes the body dispose of various infections and other diseases. The HIV virus can spread by using contaminated needles or syringes, as well as blood, breast milk, semen, and other sources. Anti-retroviral therapy is used to treat HIV/AIDS and manage the infection. Numerous drug classes work at various points in the HIV life cycle. The usage of these drugs assists patients in maintaining a healthy immune system and guards against other opportunistic infections that could be fatal. These drugs help in preventing the multiplication of the virus and hence reducing the chances of its transmission.

[756322]

Market Dynamics

HIV infection rates are growing exponentially. The UNAIDS 2021 factsheet estimates that there are about 30 million HIV-positive individuals alive currently. As a result, sales of HIV medications ascended. As more individuals are becoming aware of the virus and the available pharmacological therapies for the same, the number of people undergoing HIV therapy is rising. The factors accelerating the market revenue growth include the launch of new HIV medications, increased clinical studies, and other R&D activities. Furthermore, increasing government efforts to educate the general population about the causes, symptoms, and pharmacological therapy are also influencing the market revenue growth. However, strict drug approvals as well as the side effects associated with the consumption of few drugs, are expected to hinder the market revenue growth to some extent.

Market Ecosystem

The global market has been analyzed from three perspectives: drug class, distribution channel, and region. 

HIV Drugs Market by Drug Class

[785943]

Based on drug class, the global HIV drugs market has been segmented into, non-nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors, and combination drugs. 

The combination HIV drug segment accounts for the largest revenue share, and it is expected to maintain its dominance during the forecast period. The large revenue share of this segment can be attributed to the improving outcomes in the pharmacological treatment of HIV and co-infections and the increasing demand for this drug class. 

In 2021, the integrase inhibitors segment accounted for the second-largest revenue share and it is expected to register significant revenue growth during the forecast period. The International AIDS Society recommends integrase inhibitors as the initial pharmacological therapy for new human immunodeficiency virus infections (IAS).

HIV Drugs Market by Distribution Channel

Based on the distribution channel, the global HIV drugs market has been segmented into, online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment dominates the HIV drugs market because of the large patient footfall in the hospital for the treatment of HIV. Additionally, an increase in anti-retroviral drug prescriptions is expected to support revenue growth during the forecast period. 

HIV Drugs Market by Region  

Based on the region, the global HIV drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America accounts for the largest revenue share in the global HIV drugs market and it is expected to maintain its dominance during the forecast period. The dominance of North America can be attributed to the increasing frequency of HIV infections among the U.S. population. 

Europe is expected to be the second-largest revenue-generating market due to the concentration of known HIV drug manufacturers in the region. Additionally, increasing partnerships and collaborations between market participants to expand their footprint is expected to support the market revenue growth during the forecast period. 

On the other hand, the Asia Pacific HIV drugs market is expected to register  significant revenue growth during the forecast period because of the growing populations of China and India, and an increase in the need for HIV medications in the coming years.

Competitive Landscape

Some of the prominent players operating in the global HIV drugs market are:

• Mylan N.V.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• ViiV Healthcare Limited
• Genentech, Inc.
• Gilead Sciences, Inc.
• Merck & Co.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc.

Strategic Developments

• In August 2022, Gilead Sciences announced its marketing authorization for Sunlenca® (lenacapavir) injection and tablets for the treatment of HIV infection, granted by the European commission.
• In March 2020, AbbVie announced plans to evaluate HIV medicine Kaletra/Aluvia (lopinavir/ritonavir) as a treatment for Covid-19 caused by the novel coronavirus.

Frequently Asked Questions About This Report